Sinan Wang, PhD, joined the ShanghaiTech University in 2021 as a tenure-track Assistant Professor in the School of Biomedical Engineering. Dr. Wang obtained his PhD degree in East China University of Science and Technology. Dr. Wang completed his postdoc training in University of California, San Francisco and subsequently became an associate professional researcher.

Dr. Wang has worked in PET probe development and radionuclide therapy for many years. His research aims to explore the potential of novel biomarkers as a nuclear medicine target, and develop new drugs as molecular imaging probes. His lab needs different specialties in medicinal chemistry, biological evaluation and molecular imaging. Dr. Wang has published over 20 papers, including several first-author papers such as Clin. Cancer. Res and J. Am. Chem. Soc.  

• Development and optimization of PET probe targeting novel biomarkers

• Radionuclide therapy for cancer treatment

• Development of efficient radiolabeling methodology

• Development of boron neutron capture therapy (BNCT) reagents

Reviewer for journals:

• Molecular Pharmaceutics

• The Journal of Organic Chemistry

Member for associations or committees:

• Society of Nuclear Medicine and Molecular Imaging (SNMMI)

• American Chemical Society

• Sinan Wang*, Jun Li*, Jun Hua* Yang Su, Denis Beckford-Vera, Walter Zhao, Mayuri Jayaraman, Tony Huynh, Ning Zhao, Yung-Hua Wang, Yangjie Huang, Fujun Qin, Sui Shen, Daniel Gioeli, Robert Dreicer, Renuka Sriram, Jonathan Chou, Felix Feng, Rahul Aggarwal, Michael J. Evans, Youngho Seo, Bin Liu, Robert R. Flavell, Jiang He. Molecular imaging of prostate cancer targeting CD46 using immunoPET. Clin. Cancer Res. 2021, 5, 1305-1315.

• Sinan Wang, Charles Blaha, Raquel Santos, Tony Huynh, Thomas R. Hayes, Denis R. Beckford-Vera, Joseph E. Blecha, Andrew S. Hong, Miko Fogarty, Thomas A. Hope, David R. Raleigh, David M. Wilson, Michael J. Evans, Henry F. VanBrocklin, Tomoko Ozawa, Robert R. Flavell. Synthesis and initial biological evaluation of boron-containing prostate specific membrane antigen ligands for treatment of prostate cancer using boron neutron capture therapy. Mol. Pharmaceutics. 2019, 16, 3831-3841.

• Sinan Wang, David E. Korenchan, Paola Perez Rivera, Céline Taglang, Thomas Hayes, Renuka Sriram, Robert Bok, Andrew Hong, Henry Li, David M. Wilson, John Kurhanewicz, Robert R. Flavell. Amino Acid-Derived Sensors For Specific Zn²⁺ Detection Using Hyperpolarized ¹³C Magnetic Resonance Spectroscopy. Chem. - A Eur. J. 2019, 25, 11842-11846.

• Sinan Wang, Xiangmin Li, Hongwei Liu, Li Xu, Jinchen Zhuang, Jian Li, Hao Li, and Wei Wang. Organocatalytic enantioselective direct addition of aldehydes to 4-vinylpyridines and electrondeficient vinylarenes and their synthetic applications. J. Am. Chem. Soc., 2015, 137, 2303-2310.

• Sinan Wang*, Mingbo Su*, Jiang Wang*, Zeng Li, Lei Zhang, Jingya Li, Jia Li and Hong. Liu. (R)-3-amino-1-((3aS,7aS)-octahydro-1H-indol-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one derivatives as potent inhibitors of dipeptidyl peptidase-4: design, synthesis, biological evaluation, and molecular modeling. Bioorg. Med. Chem. 2014,22, 6684-6693.

The Molecular Imaging and Radionuclide Therapy Lab aims to develop novel PET imaging probes and radionuclide therapeutic reagents for early-stage tumor diagnosis, drug evaluation and better understanding of disease mechanism. Training opportunities in our lab are by nature interdisciplinary to meet the special challenge for nuclear medicine which requires specialties in medicinal chemistry, radiochemistry and biomedical engineering. Our lab focuses on the following research fields: 

• Development of novel PET probes

• Radionuclide therapy for cancer treatment

• Application of PET imaging in drug development